Prevention of Cardiovascular Ischemic Events

Prevention of cardiovascular ischemic events: high-risk and secondary prevention.

Atherosclerosis is a chronic disease involving the coronary, carotid, and aorto-femoral vascular beds that represents the major cause of death worldwide.1,2 Coronary artery disease (CAD) is the major cause of morbidity and mortality in the world. Efforts at preventing the clinical manifestations of atherosclerosis have yielded impressive results in the past 3 decades and constitute the major fo...

Prevention of Cardiovascular Events in Hypertension and CAD & Management of Hypertension in HF of Ischemic origin

1. Prev ntion of Cardiovascular Events in Patients With Hypertension and CAD 1.1. Antihypertensive Drugs for the Secondary Prevention of Cardiovascular Events in Patients With CAD 1.1.1. Thiazide and ThiazideType Diuretics 1.1.2. β-Blockers 1.1.3. ACE Inhibitors 1.1.4. Angiotensin Receptor Blockers 1.1.5. Aldosterone Antagonists 1.1.6. Calcium Channel Blockers 1.1.7. Direct Renin Inhibitors 2. ...

Ximelagatran in prevention of cardiovascular events.

Ximelagatran (Exanta (R) is the first oral anticoagulant in a new class of drugs called direct thrombin inhibitors. Two studies suggest that ximelagatran is at least as effective as warfarin in preventing stroke in high risk patients with atrial fibrillation. Ximelagatran may also reduce the rate of major cardiovascular events after a myocardial infarction, compared to placebo. Ximelagatran doe...

Secondary prevention of atherothrombotic events after ischemic stroke.

Atherosclerotic vascular disease is the leading cause of ischemic stroke, resulting in occlusive or severely stenotic lesions of major intracranial or extracranial arteries and narrowing of small penetrating arteries of the brain. Atherosclerosis of the coronary arteries (ie, coronary artery disease) is an indirect cause of cardioembolic stroke secondary to myocardial infarction. Ischemic heart...

Causes of Cardiovascular Ischemic Events in Giant Cell Arteritis.